Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 12/20 | 0.39 |
| ▸ | MME | P08473 | 11/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841053 | 0.93 | REN (0.42) | LTB4R2AGTR1MMEAGTR2 | |
| SCHEMBL839252 | 0.92 | AGTR1 (0.41) | LTB4R2AGTR1MME | |
| SCHEMBL839949 | 0.92 | AGTR1 (0.41) | LTB4R2AGTR1MME | |
| SCHEMBL859394 | 0.92 | AGTR1 (0.41) | LTB4R2AGTR1MME | |
| SCHEMBL839269 | 0.91 | AGTR1 (0.40) | LTB4R2AGTR1MME | |
| SCHEMBL840125 | 0.91 | AGTR1 (0.45) | LTB4R2AGTR1MME | |
| SCHEMBL841346 | 0.91 | AGTR1 (0.45) | LTB4R2AGTR1MME | |
| SCHEMBL839870 | 0.90 | AGTR1 (0.40) | LTB4R2AGTR1MMEAGTR2LPAR1 | |
| SCHEMBL839995 | 0.89 | AGTR1 (0.39) | AGTR1MMEGAAMMP8 | |
| SCHEMBL840624 | 0.88 | AGTR1 (0.38) | AGTR1MMEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143298-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |